Investment Thesis
Edgewise Therapeutics is a pre-revenue biotech company with severe cash burn of $144M in free cash flow annually, eroding equity at a -30.4% ROA despite maintaining a strong cash position of $61M. The company faces existential risk with current burn rates allowing only 4-5 quarters of operations, and no revenue generation indicates clinical-stage or failed commercialization.
Strengths
- Strong balance sheet with $522.3M stockholders equity and minimal debt ($59K)
- Excellent liquidity with 19.85x current ratio providing near-term operational cushion
- Low leverage profile with 0.00x debt-to-equity ratio reducing financial distress risk
Risks
- Massive annual cash burn of $144.1M with only ~4-5 quarters of cash runway remaining
- Zero revenue generation indicating failed product commercialization or early-stage development
- Deteriorating financial performance with negative ROE of -32.1% and ROA of -30.4%, destroying shareholder value
- Operating losses of $191.4M annually unsustainable without successful product launch or funding
Key Metrics to Watch
- Operating cash burn rate and cash runway months remaining
- Clinical trial progress and FDA approval milestones for pipeline drugs
- Revenue recognition from any approved or launched pharmaceutical products
- Equity dilution from potential secondary offerings or financing activities
Financial Metrics
Revenue
N/A
Net Income
-167.8M
EPS (Diluted)
$-1.63
Free Cash Flow
-144.1M
Total Assets
552.6M
Cash
61.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-32.1%
ROA
-30.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
19.85x
Quick Ratio
19.85x
Debt/Equity
0.00x
Debt/Assets
5.5%
Interest Coverage
N/A
Long-term Debt
59.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T16:14:10.995764 |
Data as of: 2025-12-31 |
Powered by Claude AI